Literature DB >> 9824645

Expression of the ERBB2/neu and neurofibromatosis type 1 gene products in reactive and neoplastic schwann cell proliferation.

J Schlegel1, K Muenkel, T Trenkle, G Fauser, J Ruschoff.   

Abstract

In the present study we investigated the expression of the ERBB2 protein and neurofibromin in human benign and malignant Schwann cell tumors, traumatic neuromas and peripheral nerves without pathological findings. By immunohistochemistry and Western analysis ERBB2 expression was not detectable in normal nerves but in proliferating Schwann cells of traumatic neuromas. While none of the malignant schwannomas exhibited ERBB2 expression, weak expression was seen in a small proportion of the benign schwannomas. Low levels of neurofibromin were detectable in normal nerves but not in traumatic neuromas or tumors. These data indicate an inverse expression pattern of ERBB2 and neurofibromin in human non-neoplastic Schwann cells, but not in neurinoma cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9824645     DOI: 10.3892/ijo.13.6.1281

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  3 in total

1.  Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033.

Authors:  Joshua T Dilworth; Jonathan W Wojtkowiak; Patricia Mathieu; Michael A Tainsky; John J Reiners; Raymond R Mattingly; Chad N Hancock
Journal:  Cancer Biol Ther       Date:  2008-12-07       Impact factor: 4.742

2.  Tumorigenic properties of neurofibromin-deficient neurofibroma Schwann cells.

Authors:  D Muir; D Neubauer; I T Lim; A T Yachnis; M R Wallace
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

3.  EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy.

Authors:  Nikola Holtkamp; Elke Malzer; Jan Zietsch; Ali Fuat Okuducu; Jana Mucha; Christian Mawrin; Victor-F Mautner; Hans-Ulrich Schildhaus; Andreas von Deimling
Journal:  Neuro Oncol       Date:  2008-07-23       Impact factor: 12.300

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.